Abstract:
The present invention relates to a conjugate prepared by conjugating mucosal vaccine adjuvants and allergen, and an allergen-specific immunotherapeutic agent; more specifically, to a conjugate prepared by using flagellin of vibrio vulnificus, which is a toll-like receptor-5 (TLR-5) drug and a vaccine adjuvant, and a hydrophilic multiple-bonded linker having a thiol group (-SH) of a dust mite extract; and a mucosal allergen-specific immunotherapeutic agent containing the same. [Reference numerals] (AA) Penh value (% relative to PBS); (BB) FlaB/HDM (10 μg) mixture; (CC) FlaB/HDM (3.5 μg) mixture; (DD) FlaB-HDM (3.5 μg) bonded body; (EE) Methacholine (mg/mL)
Abstract:
본 발명은 플라젤린을 포함하는 천식 및 알레르기 질환 면역 치료제에 관한 것으로서, 보다 상세하게는 플라젤린을 유효 성분으로 함유시킴으로써 천식, 아토피성 피부염, 알레르기성 비염 등과 같은 알레르기 질환에 대한 항원 특이적 면역 반응을 조절하는 면역치료제에 관한 것이다. 항원 특이적 천식 치료제, 플라젤린, 패혈증 비브리오균, 면역 치료제
Abstract:
An immuno-therapy adjuvant composition comprising flagellins is provided to be able to control antigen-specific immuno-reaction against allergic diseases such as asthma, atopic dermatitis and allergic rhinitis. The adjuvant composition for treating asthma and allergic diseases comprises flagellins of septic vibrio as an effective ingredient. In the composition, the flagellins are encoded by a gene selected from the group consisting of flaA, flaB, flaF, flaC, flaD, and flaE.